GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (OTCPK:DSRLF) » Definitions » LT-Debt-to-Total-Asset

Diasorin SpA (Diasorin SpA) LT-Debt-to-Total-Asset : 0.34 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Diasorin SpA's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.34.

Diasorin SpA's long-term debt to total assets ratio declined from Dec. 2022 (0.36) to Dec. 2023 (0.34). It may suggest that Diasorin SpA is progressively becoming less dependent on debt to grow their business.


Diasorin SpA LT-Debt-to-Total-Asset Historical Data

The historical data trend for Diasorin SpA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA LT-Debt-to-Total-Asset Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.40 0.36 0.34

Diasorin SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 - - - 0.34

Diasorin SpA LT-Debt-to-Total-Asset Calculation

Diasorin SpA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=1181.032/3502.115
=0.34

Diasorin SpA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=1181.032/3502.115
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA  (OTCPK:DSRLF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Diasorin SpA LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA (Diasorin SpA) Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin SpA is a biotechnology company engaged in developing, producing, and marketing reagent kits for laboratory diagnostics around the world. The business has focused on the immunodiagnostic market, molecular diagnostics, and Life Science sector. The company has a presence in Italy, Europe, North America, and the Rest of the world, where the majority of its revenue is from North America followed by Italy.